SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-17-154107
Filing Date
2017-05-02
Accepted
2017-05-02 16:45:54
Documents
46
Period of Report
2017-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q d378762d10q.htm 10-Q 530707
2 EX-31.1 d378762dex311.htm EX-31.1 6694
3 EX-31.2 d378762dex312.htm EX-31.2 6674
4 EX-32.1 d378762dex321.htm EX-32.1 4006
11 GRAPHIC g378762g57k66.jpg GRAPHIC 172106
  Complete submission text file 0001193125-17-154107.txt   2436593

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE DOCUMENT ntla-20170331.xml EX-101.INS 302416
6 XBRL TAXONOMY EXTENSION SCHEMA ntla-20170331.xsd EX-101.SCH 27694
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE ntla-20170331_cal.xml EX-101.CAL 33807
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE ntla-20170331_def.xml EX-101.DEF 68854
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE ntla-20170331_lab.xml EX-101.LAB 227316
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ntla-20170331_pre.xml EX-101.PRE 150720
Mailing Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139
Business Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139 857-285-6200
Intellia Therapeutics, Inc. (Filer) CIK: 0001652130 (see all company filings)

IRS No.: 364785571 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37766 | Film No.: 17805739
SIC: 2835 In Vitro & In Vivo Diagnostic Substances